Anthracycline-based chemotherapy can result in the development of a cumulative and
progressively develo** cardiomyopathy. Doxorubicin is one of the most highly prescribed …

Doxorubicin is utilized for anti-neoplastic treatment for several decades. The utility of this
drug is limited due to its side effects. Generally, doxorubicin toxicity is originated from the …

Many cancer therapies produce toxic side effects whose molecular mechanisms await full
elucidation. The most feared and studied side effect of chemotherapeutic drugs is …

Doxorubicin (DOX) is an anticancer anthracycline that presents a dose‐dependent and
cumulative cardiotoxicity as one of the most serious side effects. Several hypotheses have …

Anthracyclines are the cornerstone of many chemotherapy regimens for a variety of cancers.
Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite …

Doxorubicin (DOX) is an anthracycline antibiotic widely used as a chemotherapeutic agent
to treat solid tumours and hematologic malignancies. Although useful in the treatment of …

Purpose Doxorubicin (DOX) is a highly active antineoplastic agent; however, its clinical use
is limited due to associated cardiotoxicity. This study was performed to evaluate the …

Cardiotoxicity is a significant complication of chemotherapeutic agents in cancer patients.
Cardiovascular incidents including LV dysfunction, heart failure (HF), severe arrhythmias …

Doxorubicin is an extensively used anti-neoplastic drug used for solid and hematogenous
cancer since the 1950s, and its usage is limited due to its toxic effects upon various organs …

The use of the adjuvant therapeutic antibody trastuzumab in breast cancer is associated with
a range of cardiotoxic side effects despite successfully reducing the severity of outcomes …